PT  - JOURNAL ARTICLE
AU  - Restivo, Domenico A.
AU  - Casabona, Antonino
AU  - Nicotra, Alessia
AU  - Zappia, Mario
AU  - Elia, Maurizio
AU  - Romano, Marcello C.
AU  - Alfonsi, Enrico
AU  - Marchese-Ragona, Rosario
TI  - ALS dysphagia pathophysiology
AID  - 10.1212/WNL.0b013e318281cc1b
DP  - 2013 Feb 12
TA  - Neurology
PG  - 616--620
VI  - 80
IP  - 7
4099  - http://n.neurology.org/content/80/7/616.short
4100  - http://n.neurology.org/content/80/7/616.full
SO  - Neurology2013 Feb 12; 80
AB  - Objectives: This study looked at the effect of botulinum toxin type A (BoTox-A) in patients with amyotrophic lateral sclerosis (ALS) with dysphagia due to isolated upper motor neuron (UMN) involvement or combined UMN/lower motor neuron (LMN) impairment associated with oral phase or oropharyngeal muscles involvement. Establishing whether different pathophysiologic mechanisms underlie different responses to BoTox-A treatment may have important implications for patient management.Patients and methods: We screened 35 patients with sporadic ALS with dysphagia and included in the study 20 out of 35 with upper esophageal sphincter (UES) hyperactivity. We divided these 20 patients into 2 groups, based on the presence or absence of LMN impairment. Irrespective of the groups, we treated all 20 patients with BoTox-A injected into the UES. The study outcome was dysphagia severity scored using the Penetration/Aspiration Scale (PAS), measured before and 2, 4, and 20 weeks after injection.Results: Significant mean PAS reduction was noted at weeks 2 and 4. The botulinum-dependent PAS reduction was entirely associated with the variability shown by the group of patients with no sign of LMN impairment (group 2) and was not observed in group 1.Conclusions: The significant improvement observed in patients with isolated UES dysfunction suggests that a different pathophysiology of ALS dysphagia predisposes patients to a different response to treatment with BoTox-A. This treatment may represent an alternative treatment to percutaneous endoscopic gastrostomy (PEG) or prolong PEG-free time.Classification of evidence: This study provides Class III evidence that botulinum is more effective at 2 and 4 weeks in improving dysphagia in patients with ALS with UES hyperactivity without LMN involvement (vs those with LMN involvement).ALS=amyotrophic lateral sclerosis; BoTox-A=botulinum toxin type A; CP=cricopharyngeal; IC=inferior constrictor; LMN=lower motor neuron; MS=multiple sclerosis; PAS=Penetration/Aspiration Scale; PD=Parkinson disease; PEG=percutaneous endoscopic gastrostomy; UES=upper esophageal sphincter; UMN=upper motor neuron